ESMO Breast Cancer Virtual Meeting | Conference

Dr. Andre on Strategies to Improve Outcomes in Breast Cancer

May 28th 2020

Fabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.

Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 28th 2020

Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

May 27th 2020

The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).

Top Priorities Outlined in Next Decade of Breast Cancer Research

May 26th 2020

Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.

LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer

May 26th 2020

LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets

May 24th 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

Mindful Adaptation of Breast Cancer Treatment Necessary Amid COVID-19 Crisis

May 24th 2020

Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.

Ipatasertib Survival Results Continue to Impress in TNBC

May 23rd 2020

Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer.

Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 23rd 2020

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.

Dr. Dent on Final LOTUS Findings in TNBC

May 23rd 2020

Rebecca Dent, MD, discusses the findings from the phase 2 LOTUS trial that treated patients with inoperable locally advanced/metastatic triple-negative breast cancer with first-line ipatasertib plus paclitaxel.